Table 4 Cox regression results for the type of oncological therapy
From: Use of symptom-focused oncological cancer therapies in hospices: a retrospective analysis
Hazard Ratio | 95% Confidence Interval | p | |
|---|---|---|---|
Hospice | 1.02 | [0.86,1.2] | 0.8329 |
Age | 1.01 | [1,1.02] | 0.0212 |
Sex (female) | 0.82 | [0.68,0.99] | 0.0416 |
Gastrointestinal cancer | 0.92 | [0.72,1.17] | 0.4854 |
Gynaecological cancer | 0.86 | [0.65,1.13] | 0.2805 |
Haematological systemic disease | 1.38 | [0.93,2.07] | 0.1133 |
Brain cancer | 0.62 | [0.45,0.87] | 0.0053 |
ENT tract cancer | 0.69 | [0.45,1.06] | 0.0873 |
Other cancer | 0.75 | [0.49,1.13] | 0.1626 |
Urological cancer | 0.94 | [0.67,1.32] | 0.7376 |
Anti-hormonal therapy | 0.47 | [0.18,1.18] | 0.1064 |
Radiotherapy | 0.54 | [0.22,1.36] | 0.1929 |
Bisphosphonates | 0.48 | [0.25,0.91] | 0.0254 |
Chemotherapy | 1.49 | [0.62,3.62] | 0.3751 |
Transfusions | 0.5 | [0.24,1.02] | 0.0564 |
Targeted therapies | 0.41 | [0.15,1.1] | 0.0771 |